Honoré, B.; Andersen, M.D.; Wilken, D.; Kamper, P.; d’Amore, F.; Hamilton-Dutoit, S.; Ludvigsen, M.
Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling. Cancers 2022, 14, 247.
https://doi.org/10.3390/cancers14010247
AMA Style
Honoré B, Andersen MD, Wilken D, Kamper P, d’Amore F, Hamilton-Dutoit S, Ludvigsen M.
Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling. Cancers. 2022; 14(1):247.
https://doi.org/10.3390/cancers14010247
Chicago/Turabian Style
Honoré, Bent, Maja Dam Andersen, Diani Wilken, Peter Kamper, Francesco d’Amore, Stephen Hamilton-Dutoit, and Maja Ludvigsen.
2022. "Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling" Cancers 14, no. 1: 247.
https://doi.org/10.3390/cancers14010247
APA Style
Honoré, B., Andersen, M. D., Wilken, D., Kamper, P., d’Amore, F., Hamilton-Dutoit, S., & Ludvigsen, M.
(2022). Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling. Cancers, 14(1), 247.
https://doi.org/10.3390/cancers14010247